An advanced fatty liver disease panel is a comprehensive set of blood tests and non-invasive assessments used to evaluate the risk of liver scarring (fibrosis) in people with non-alcoholic fatty liver disease (NAFLD). In the UK, NICE recommends these panels to identify patients at risk of advanced fibrosis, which can progress to cirrhosis if unmanaged. The panel typically includes liver function tests, calculated fibrosis scores such as FIB-4, and the Enhanced Liver Fibrosis (ELF) test for high-risk cases. Because fatty liver disease often develops without symptoms, early detection through these tests is crucial for timely intervention and preventing serious liver damage.

What Is an Advanced Fatty Liver Disease Panel?

An advanced fatty liver disease panel is a comprehensive set of blood tests and non-invasive assessments used to evaluate the risk of advanced liver fibrosis (scarring) in individuals with non-alcoholic fatty liver disease (NAFLD). In the UK, NAFLD is also increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), though current NICE guidance and NHS resources predominantly use the term NAFLD.

These tests help clinicians estimate whether simple fat accumulation in the liver has progressed to significant fibrosis, which may lead to cirrhosis or liver failure if left unmanaged. It is important to understand that non-invasive tests primarily assess the risk of advanced fibrosis; they do not diagnose non-alcoholic steatohepatitis (NASH or MASH), which typically requires liver biopsy in selected cases.

The panel serves as an important diagnostic tool because fatty liver disease often develops silently, with many patients experiencing no symptoms until significant liver damage has occurred. According to NICE guidance (NG49), early identification of advanced fibrosis is crucial as it allows for timely intervention and monitoring to prevent progression to cirrhosis.

Key purposes of the panel include:

• Estimating the risk of advanced liver fibrosis

• Stratifying patients into risk categories for disease progression

• Monitoring disease progression over time

• Guiding treatment decisions and lifestyle interventions

• Identifying patients who may require specialist hepatology referral

NICE recommends that all adults with NAFLD undergo non-invasive fibrosis risk stratification, not only those with additional risk factors. The recommended pathway uses blood-based scoring systems (FIB-4 or NAFLD Fibrosis Score) as first-line tests, followed by the Enhanced Liver Fibrosis (ELF) test if results are indeterminate or high-risk. This approach represents a non-invasive alternative to liver biopsy in many cases, providing valuable information about liver health whilst avoiding the risks associated with invasive procedures.

What Tests Are Included in the Panel?

An advanced fatty liver disease panel typically comprises several complementary tests that together provide a comprehensive assessment of liver function and fibrosis risk. The specific components may vary between healthcare providers, but UK pathways follow NICE recommendations combining blood biomarkers and calculated scoring systems.

Standard blood tests commonly included:

• Liver function tests (LFTs): Measuring alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), bilirubin, and albumin levels

• Full blood count: Assessing platelet count, which can indicate advanced fibrosis when reduced

• Metabolic markers: Including fasting glucose, HbA1c, lipid profile (cholesterol and triglycerides)

Calculated fibrosis scores are derived from these blood results and form the first-line assessment:

• FIB-4 index: Uses age, AST, ALT, and platelet count to estimate fibrosis stage. UK practice uses age-adjusted thresholds: for adults under 65 years, low risk is <1.3 and high risk is >2.67; for those aged 65 and over, low risk is <2.0 and high risk is >2.67

• NAFLD Fibrosis Score (NFS): Incorporates age, BMI, diabetes status, AST/ALT ratio, platelet count, and albumin. Age-adjusted thresholds are also applied in clinical practice

Second-line testing is recommended by NICE when first-line scores are indeterminate or high-risk:

• Enhanced Liver Fibrosis (ELF) test: A proprietary blood test combining three direct fibrosis markers (hyaluronic acid, procollagen III N-terminal peptide [PIIINP], and tissue inhibitor of metalloproteinases 1 [TIMP-1]). NICE diagnostic guidance (DG34) recommends the ELF test for assessing advanced fibrosis in NAFLD, with a threshold of 10.51 or above indicating likely advanced fibrosis and warranting specialist referral

Some pathways may also include transient elastography (FibroScan®), a specialised ultrasound technique that measures liver stiffness as a proxy for fibrosis. FibroScan is a CE/UKCA-marked medical device regulated by the MHRA and is widely used in the NHS where locally available. It provides a Controlled Attenuation Parameter (CAP) score for fat quantification and a liver stiffness measurement (LSM) for fibrosis assessment, offering complementary information to blood-based tests. The inclusion of elastography depends on local availability and care pathways.

Understanding Your Advanced Fatty Liver Disease Panel Results

Interpreting advanced fatty liver disease panel results requires understanding both individual test values and composite scores. Your healthcare provider will review these results in the context of your overall health, medical history, and risk factors. It is important to remember that these tests estimate the risk of advanced fibrosis; they do not confirm or exclude NASH, and normal liver enzyme levels do not rule out significant fibrosis.

Liver enzyme patterns provide initial insights into liver health. Elevated ALT and AST levels suggest liver cell damage, though normal values do not exclude significant liver disease. In NAFLD, the AST/ALT ratio is typically less than 1, whilst ratios above 1 may indicate more advanced fibrosis or alternative diagnoses. GGT elevation often correlates with metabolic syndrome and insulin resistance, common features in fatty liver disease.

Fibrosis score interpretation helps stratify disease severity using age-adjusted thresholds:

• FIB-4 scores: For adults under 65 years, scores below 1.3 indicate low probability of advanced fibrosis, whilst scores above 2.67 suggest high probability. For those aged 65 and over, the low-risk threshold is <2.0. Indeterminate or high-risk scores warrant second-line ELF testing

• NAFLD Fibrosis Scores: Generally, scores below -1.455 indicate low risk and scores above 0.676 suggest high risk, with intermediate scores requiring further assessment. Age-adjusted thresholds are applied in practice

• ELF test scores: According to NICE guidance (DG34), scores of 10.51 or above indicate likely advanced fibrosis and warrant hepatology referral. Scores below 10.51 suggest low likelihood of advanced fibrosis

It is important to recognise that these tests have limitations and should be interpreted in clinical context. Acute illness, certain medications, and other liver conditions can affect results. No single test perfectly predicts liver fibrosis, which is why the NICE pathway combines multiple markers sequentially. Indeterminate results require second-line testing with the ELF test or, where available, transient elastography.

Metabolic markers within the panel also provide valuable context. Elevated HbA1c or fasting glucose indicates diabetes or prediabetes, which accelerates liver disease progression. Dyslipidaemia (abnormal cholesterol levels) commonly accompanies NAFLD and requires management to reduce cardiovascular risk, which represents the leading cause of mortality in NAFLD patients. Your results should be discussed thoroughly with your GP or specialist, who can explain what the findings mean specifically for your situation and health trajectory.

Next Steps After Your Panel Results

The actions following your advanced fatty liver disease panel results depend on the severity of findings and your individual risk profile. Your healthcare team will develop a personalised management plan based on these results and NICE guidance.

For low-risk results (indicating low probability of advanced fibrosis), the primary focus is on lifestyle modification to prevent disease progression:

• Weight management: Achieving 7–10% body weight loss can significantly reduce liver fat and inflammation

• Dietary changes: Following a Mediterranean-style diet, reducing refined carbohydrates and saturated fats

• Regular physical activity: Aiming for at least 150 minutes of moderate-intensity exercise weekly, as recommended by the NHS

• Alcohol limitation: Following UK Chief Medical Officers' guidance of no more than 14 units per week, spread over at least three days, with several alcohol-free days each week

• Optimising metabolic health: Managing diabetes, hypertension, and cholesterol through medication and lifestyle changes

Your GP will typically arrange repeat testing every three years to monitor for disease progression, or sooner if your clinical situation changes, in line with NICE recommendations.

For indeterminate or high-risk first-line results, second-line testing with the ELF test is recommended. If the ELF score is 10.51 or above, specialist hepatology referral is advised according to NICE guidance. Local pathways may vary, and some areas use transient elastography as part of the assessment. A hepatologist can provide:

• More detailed assessment including possible FibroScan or, in selected cases, liver biopsy

• Screening for complications such as portal hypertension (in advanced fibrosis or cirrhosis)

• Hepatocellular carcinoma (HCC) surveillance for people with cirrhosis

• Consideration of specialist treatments: currently, no medicines are licensed for NASH in the UK, but under specialist care, pioglitazone or vitamin E may be considered in selected biopsy-proven cases after discussing risks and benefits, as per NICE guidance

• Enhanced monitoring protocols

When to seek urgent or emergency care:

• Call 999 or go to A&E immediately if you experience vomiting blood, passing black or tarry stools, or new confusion or altered mental state

• Contact your GP urgently if you develop jaundice (yellowing of skin or eyes), persistent abdominal swelling or pain, or unexplained bruising or bleeding

• For non-urgent advice, contact NHS 111 or your GP surgery

Regardless of your results, addressing cardiovascular risk factors remains paramount, as heart disease represents the most common cause of death in people with NAFLD. This includes managing blood pressure, cholesterol, and diabetes, alongside smoking cessation if applicable. Your healthcare team may prescribe medications such as statins, which should not be withheld solely because of NAFLD; they are safe in fatty liver disease and provide important cardiovascular protection when indicated by your overall CVD risk, in line with NICE guidance. Liver function tests are monitored as standard when taking statins. Regular follow-up and adherence to recommended lifestyle changes offer the best opportunity to prevent progression and maintain long-term liver health.

Frequently Asked Questions